
# Simpli-Fi Automation

Al-Powered Sensing Solutions for Life



Simpli-Fi is addressing a \$25B healthcare system inefficiency by leveraging advancements in AI combined with NASA e-Nose technology. Our unique solution will protect patients against hospital-acquired infections and provide next-gen Remote Patient Monitoring using the sense of smell (sensor VOC smelling capabilities).

#### **Hospital-Acquired Infection Monitoring**

Current-2023 (US) \$11.6 Billion Projected- 2028 (US) \$16.4 Billion CAGR 6.65%

\*According to a MarketsandMarkets report published Feb 2024

#### **US Remote Patient Monitoring Device**

Current-2022 (US) **\$13.40 Billion** 

Projected- 2028 (US) \$25.28 Billion

CAGR: 11.6%

\* According to an Arizton Advisory & Intelligence report published June 2023

TAM: \$25B US combined Patient and clinical environmental monitoring SAM: \$3B SOM: \$150M






HAI's, contracted within healthcare facilities, can lead to severe complications, prolonged hospital stays, increased healthcare costs, and even mortality. Despite stringent hygiene protocols, the complex and dynamic nature of hospital environments makes it challenging to completely eliminate the risk of HAIs. A new method of monitoring the clinical environment for these hazards is needed to reduce the cost of care and improve patient outcomes.

## Sensing Solutions for Life The power of the chemical lab, anywhere, anytime.

Our unique hybrid SaaS solution protects patients from hospital-acquired infection by leveraging the NASA e-Nose, a carbon nanotube-based VOC sensor that provides quantitative and qualitative measurement of target molecules related to infection. In addition, this technology platform can be used to provide non-invasive remote patient monitoring by measuring various breath biomarkers related to chronic disease.



- Provides real-time detection of airborne pathogens.
- Monitors wound care and post-surgical recovery.
- Leverages AI models to detect and classify the "odors" of disease in the air and on human breath.
- Can be used in the clinic or the home environment.





## Why Simpli-Fi Hybrid SaaS?

#### **Key SaaS Features**

#### 1. Clinical Environment Monitoring:

- Continuous Surveillance: Our SaaS platform continuously monitors air quality in hospitals and nursing homes, detecting pathogens like C-Diff, MRSA, and Staph infections. This proactive approach helps in preventing the spread of HAIs.
- Automated Alerts and Reporting: The system generates real-time alerts and detailed reports for healthcare administrators, facilitating prompt intervention and ensuring compliance with health and safety regulations.

#### 2. Al-Powered Disease Diagnostics:

- Non-Invasive Breath Analysis: Our software uses Al to analyze breath samples, detecting biomarkers associated with various diseases such as respiratory infections, metabolic disorders, and even certain cancers. This non-invasive method offers a quick, painless, and highly accurate diagnostic tool.
- Real-Time Results: Patients receive immediate feedback, enabling faster diagnosis and treatment. This feature is particularly beneficial for early detection and management of chronic diseases.

#### Benefits of Cloud Computing in Healthcare





#### Impact on the Healthcare System

The implementation of **Simpli-Fi**'s hybrid SaaS model is poised to transform the healthcare landscape by:

- •Reducing Healthcare Costs: Early and accurate disease detection can significantly reduce treatment costs and hospital stays. Additionally, preventing HAIs can save billions in healthcare expenses annually.
- •Improving Patient Outcomes: Non-invasive diagnostics and timely interventions lead to better patient outcomes, enhancing the overall quality of care and patient experience (non-invasive solution).
- •Enhancing Operational Efficiency: Automated monitoring and reporting streamline hospital operations, allowing healthcare professionals to focus more on patient care rather than administrative tasks.
- •Promoting Public Health: By reducing the incidence of HAIs and enabling early disease detection, our technology contributes to a healthier population and a more resilient healthcare system.
- •Simpli-Fi is committed to leveraging cutting-edge software sensing technology to create a safer, more efficient, and patient-centric healthcare environment. Our hybrid SaaS solutions are not just innovations; they are essential tools for the future of healthcare.

The Simpli-Fi Automation Team has over 290 years of combined experience in automated software engineering, remote patient monitoring (RPM), device engineering, infectious disease control, advanced manufacturing, applied materials, and business development. We are uniquely positioned to bring our hybrid SaaS solutions to the market with our diverse group of contributors and founders. Our board of directors is comprised of industry leaders, with former and current executives from 3M, Cargill, Best Buy, and Integris.

#### **Executive Team**



Chris Campbell CEO



Dr. Jev Cunningham CTO



Dr. Tim Campbell CMO



William "DJ" Dozier
Business Development



Lauren Kelly
Operations Director

#### **Board of Directors**



**Patrick Deconinck** 



**Cordell Hardy** 



Michael Wright



Amelia Hardy



Jerome Hamilton





#### **Our Partners**



"We are enthusiastic about the possibilities this collaboration holds and look forward to working closely with Simpli-Fi Automation, Inc. to advance medical diagnostics and improve patient care."

Dr. Alon Ben-Ari, CMIO Veterans Health Administration



"This technology has the potential to revolutionize remote health monitoring and provide a non-invasive tool for improving health outcomes for patients worldwide."

Dr. Bruce D. Johnson, Department of Cardiovascular Medicine, Mayo Clinic



"The potential to mitigate the impact of hospital-transmitted diseases like C-Diff is particularly noteworthy, as it can significantly improve patient safety and quality of care."

Dr. Sundar Manickam, Assistant Professor of Medicine, Cleveland Clinic Foundation



"We see immediate application uses in our mobile devices such as smartphones and wearables for fitness, wellness, and telehealth care. In addition, this sensor could be used in applications from food quality monitoring to environmental air quality monitoring through our network of partners and subsidiaries"

David Chon, Lead-MX Open Innovation, Samsung Research America















Introducing:

# Provectus Canary Clinical Environmental Monitoring

The Provectus Canary System provides continuous monitoring for airborne infectious Hazards:

- Measures Particulate Matter (PM), Temperature, Humidity, Carbon Dioxide (CO2), and VOC's
- Cost-effective C-Diff (Clostridium Difficile) monitoring in environmental room air.
- Uses "scent mapping" to detect airborne pathogens including, Staphylococcus, E. Coli, Streptococcus, Pseudomonas aeruginosa, and more.



**Operating Room Air Quality Monitoring** 







Introducing:

## Provectus Telehealth

The Provectus Telehealth system uses **breath biomarker** diagnostic technology to provide continuous access to healthcare monitoring to everyone, everywhere:

- Personalized Healthcare:
- Early Detection of Illnesses
- Early Preventive Healthcare
- Non-Invasive Monitoring
- Remote Health Monitoring










## Our Model: Hybrid SaaS

Al-powered Healthcare Software as a Service



#### 

- •Pricing: \$29.99/month for direct users, \$19.99/month for enterprise users.
- •Description: Provectus Telehealth leverages AI to monitor volatile organic compounds (VOCs) in breath, providing telehealth companies with continuous health monitoring and early disease diagnostics. This service empowers proactive healthcare management, enhancing patient care and reducing healthcare costs.



## Provectus Canary Monthly subscription

- •Pricing: \$60/month per device.
- •Description: Provectus Canary software is tailored for hospitals and nursing homes, offering real-time monitoring for hospital-acquired infections (HAIs) such as C-Diff and MRSA. By preventing the spread of infections, this service helps lower the cost of care and protects both patients and healthcare facilities.

## Airborne Infectious Disease Detection Competitive Landscape



**Sartorius MD8 Airscan**: Measures environmental/ microbial air monitoring for cleanrooms, hospitals, and sterile manufacturing. Actively samples airborne viruses, bacteria, yeast, and fungi. Provides real time alerts. Require changing filters every 8 hours.

Device cost: \$14,060 Monthly Filter cost: \$250



Monthly Filter cost: \$360

**BioSpot-GEM Bioaerosol Sampler**: Collects airborne pathogens for testing and analysis. Does not provide real time monitoring but requires lab analysis by a professional IAQ tech. Requires filter changes every 8 hours.

Device cost: \$890

Monthly Subscription: \$74.17/Mo



**Sensio Air Particle Detector**: Measures and tracks mold, pet dander, pollen, and dust mites. They are working toward detecting bacterial infections and viral pathogens. Uses spectrum analysis to identify particle sizes. Tracking of Bacteria and Viruses is in development.

Device cost: \$169

Monthly Subscription: \$33/Mo




**HibouAir Indoor air quality sensors**: Measures and tracks total VOC count, CO2, pressure, temperature, humidity, and noise. Does not detect bacterial or viral infection.

Device Comparison	Bacterial Infection	Fungal Infection	Viral Infection	Total VOC	CO2 Monitor	Temperature	Humidity	Pressure	Particulate Matter	Device Cost	Monthly Cost	
Provectus Canary	X	X	X	X	X	X	X	X		\$279	\$60	
MD8	X	X	X							\$14,060	\$250	
BioSpot-GEM	X	X	X							\$13,090	\$360	
Sensio Air	X		X						X	\$890	\$74.17	
HibouAir				X	X	X	X	X	X	\$169	\$33	





### Revenue Forecast




<sup>\*</sup> This pitch deck contains forward-looking financials that involve several risks and uncertainties. Actual results could materially differ from those anticipated.

The ask: We are seeking a total of \$10,000,000 during our seed round in exchange for 10% equity ownership in Simpli-Fi or a convertible note bearing interest with a discounted conversion within 12 months.

#### **Use of Funds-**

- Continued R&D- 40%: We have completed the beta prototype design and are now moving into testing and validation.
- Pre-Clinical trials- 10%: We are self-funding our pre-clinical trials with the Veterans Administration and Mayo Clinic.
- Manufacturing tooling and setup- 10%: we are setting up our manufacturing facility in St. Paul MN with \$1.2m in funding assistance from the Department of Employment and Economic Development (DEED).
- Operations- 20%: We are taking possession of our new nanofabrication development facility and need operational funding.
- Marketing/Product Rollout- 20%: We are releasing our line of Provectus Products in Q3 2025.





#### Milestones

Company milestone: 100 commercial automation engineering contractions

"Friends and Family" Funding of \$100,000 Jan 22 (Brown Venture Group)

- Pre-Seed Round Funding of \$450,000 (Brown Venture Group)
- Device Hardware Engineering and Development Completed
- Sensor Production-initial run of 1000 sensors
- \$4M SEED round
- FDA registration for Provectus Telehealth
- FDA 510k submission for Provectus Canary
- Clinical trials for Provectus Canary and Sport



- Company formation
- Early concept and technology design

- Pandemic Disruption
- Released 90% of staff and all contracts cancelled, not in-progress

- NASA Technology Partnership-Research License Executed
- **Provisional Patent filed**
- Alpha Prototype completed

- Provectus Sport Beta Prototype
- Provectus Canary Beta Prototype

Full Market Release of Provectus Telehealth

- Veterans Health Administration Live Demo (Canary)- Jan 2025
- Veterans Health Administration Pilot (Canary)-March 2025
- Veterans Health Administration Live Demo (Provectus Telehealth) May 2025
- FDA 510k submission for Provectus Canary-May 2025
- Veterans Health Administration Pilot (Provectus Telehealth)-May 2025
- Cleveland Clinic Pilot (Canary) June 2025
- FDA registration (Class 1 exempt) for Provectus Telehealth- July 2025

- Market Roll out for Provectus Canary-August 2025
- Market Rollout of Provectus Telehealth-Sept 2025
- FDA 510k submission for Provectus Canary-June 2025
- Full market release of Canary-Jan 2026
- Full Market Rollout of Provectus Telehealth- March 2026



<sup>\*</sup>This slide contains future projections which are not guaranteed

## Thank You!



chris@simplifiautomation.com



https://simplifiautomation.com/



1-863-289-8774



370 Wabasha St. N. Suite 700 Saint Paul, MN 55102 United States

